# Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects

Study · id `cardio:ct-nct03153137` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03153137](<https://clinicaltrials.gov/study/NCT03153137>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03153137

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 142 participants.

## Technical summary

Registry record NCT03153137. Randomized; quadruple masking; primary purpose treatment. Start 2017-08-14 (actual); primary completion 2021-06-30 (actual). Results posted on 2022-09-13.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 142 participants (enrolled count; ClinicalTrials.gov record NCT03153137, source copy `cardio:ctgov-nct03153137-2025-03-30`, retrieved 2026-10-26)
- Started: 2017-08-14 (actual) (ClinicalTrials.gov record NCT03153137, source copy `cardio:ctgov-nct03153137-2025-03-30`, retrieved 2026-10-26)
- Primary completion: 2021-06-30 (actual) (ClinicalTrials.gov record NCT03153137, source copy `cardio:ctgov-nct03153137-2025-03-30`, retrieved 2026-10-26)
- Completion: 2021-07-26 (actual) (ClinicalTrials.gov record NCT03153137, source copy `cardio:ctgov-nct03153137-2025-03-30`, retrieved 2026-10-26)
- Results first posted: 2022-09-13 (ClinicalTrials.gov record NCT03153137, source copy `cardio:ctgov-nct03153137-2025-03-30`, retrieved 2026-10-26)
- Countries: United States; Australia; Canada; China; Czechia; Denmark; France; Germany; New Zealand; Poland; Taiwan; United Kingdom (ClinicalTrials.gov record NCT03153137, source copy `cardio:ctgov-nct03153137-2025-03-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03153137-2025-03-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects
- Acronym: RUBATO
- Condition: Congenital Heart Disease
- Intervention (Drug): Macitentan 10 mg
- Intervention (Drug): Placebo
- Lead sponsor: Actelion
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)
- Registry lists this organization as the lead sponsor: Actelion (`cardio:org-actelion`)

## Provenance

Content hash: cf6c166901925285ae73bf14d7b8d22f034085ee7c0122cdf403726ab147f274
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
